Application | Comment | Organism |
---|---|---|
medicine | targeting both polyamine biosynthesis via ODC through 2-difluoromethylornithine and polyamine transport through MQT 1426 from the tumor microenvironment enhances the efficacy of polyamine-based therapy in this mouse model of squamous cell carcinoma, overview | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-difluoromethylornithine | DFMO, is used in therapy combined with MQT 1426, a polyamine transport inhibitor, for treatment of squamous cell carcinoma in a mouse model, K6/ODC | Mus musculus | |
additional information | MQT 1426 has no inhibitory effect on squamous cell carcinoma ODC activity nor does it enhance the inhibition by 2-difluoromethylornithine, but it reduces the polyamine levels in squamous cell carcinoma cells | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-ornithine | Mus musculus | - |
putrescine + CO2 | - |
? | |
L-ornithine | Mus musculus C57BL/6J | - |
putrescine + CO2 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | P00860 | - |
- |
Mus musculus C57BL/6J | P00860 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
squamous cell carcinoma cell | - |
Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-ornithine | - |
Mus musculus | putrescine + CO2 | - |
? | |
L-ornithine | - |
Mus musculus C57BL/6J | putrescine + CO2 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
ODC | - |
Mus musculus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
pyridoxal 5'-phosphate | - |
Mus musculus |
General Information | Comment | Organism |
---|---|---|
physiological function | enzyme ODC is involved in polyamine biosynthesis and squamous cell carcinoma proliferation | Mus musculus |